Home » Stocks » PRAX

Praxis Precision Medicines, Inc. (PRAX)

Stock Price: $56.51 USD 0.06 (0.10%)
Updated Jan 25, 2021 2:10 PM EST - Market open
Market Cap 2.16B
Revenue (ttm) n/a
Net Income (ttm) -44.49M
Shares Out 36.74M
EPS (ttm) -1.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $56.51
Previous Close $56.45
Change ($) 0.06
Change (%) 0.10%
Day's Open 56.87
Day's Range 55.36 - 58.30
Day's Volume 25,009
52-Week Range 27.25 - 60.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the developmen...

GlobeNewsWire - 2 months ago

- Praxis expects to initiate Phase 2/3 clinical trial for PRAX-114 in MDD in 1H21 -

PRNewsWire - 2 months ago

NEW YORK, Nov. 11, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. ("Praxis" or the "Company") (NASDAQ: PRAX). Such invest...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the developmen...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the developmen...

Seeking Alpha - 3 months ago

Nine IPOs and five SPACs went public this past week, and one IPO postponed.

Other stocks mentioned: ALGS, ARRY, CDAK, EBC, OPT, SPEL, TARS
GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the developmen...

Market Watch - 3 months ago

Praxis Precision Medicines Inc. has increased the number of shares it plans to sell in its initial public offering by 35%, as the Massachusetts-based biopharmaceutical company developing treat...

Seeking Alpha - 3 months ago

Praxis Precision Medicines has filed proposed terms for its U.S. IPO.

Market Watch - 3 months ago

Praxis Precision Medicines Inc. set terms for its initial public offering, in which the Massachusetts-based biopharmaceutical company developing treatments for central nervous system disorders...

About PRAX

Praxis Precision Medicines, a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremo... [Read more...]

Industry
Biotechnology
IPO Date
Oct 16, 2020
Stock Exchange
NASDAQ
Ticker Symbol
PRAX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for PRAX stock is "Strong Buy." The 12-month stock price forecast is 65.33, which is an increase of 15.62% from the latest price.

Price Target
$65.33
(15.62% upside)
Analyst Consensus: Strong Buy